CervoMed’s Neflamapimod Gains Entry into UK’s EXPERTS-ALS Platform for ALS Treatment Evaluation
Event summary
- CervoMed’s neflamapimod selected for inclusion in the UK EXPERTS-ALS platform to evaluate its potential in treating ALS.
- Trial funded by UK government and motor neuron disease charities, with first ALS patient expected to be dosed by end of 2026.
- Neflamapimod will be evaluated in approximately 35 ALS patients initially, with potential expansion to 80 patients.
- EXPERTS-ALS platform uses neurofilament light chain (NfL) as a biomarker to measure neuroaxonal damage in ALS patients.
- CervoMed maintains focus on dementia with Lewy bodies (DLB) and plans to initiate a Phase 3 trial in DLB later in 2026.
The big picture
CervoMed’s inclusion in the EXPERTS-ALS platform underscores the growing emphasis on biomarker-driven clinical trials to accelerate the development of treatments for neurodegenerative diseases. The UK’s investment in the platform highlights the strategic importance of public-private partnerships in advancing therapies for rare and debilitating conditions like ALS. CervoMed’s dual focus on ALS and DLB positions it at the intersection of two critical areas in neurodegenerative research.
What we're watching
- Clinical Efficacy
- Whether neflamapimod can demonstrate meaningful impact on NfL levels and clinical outcomes in ALS patients.
- Trial Execution
- The pace at which the EXPERTS-ALS platform can enroll and evaluate neflamapimod in ALS patients.
- Strategic Focus
- How CervoMed balances its primary focus on DLB while advancing neflamapimod in ALS.
Related topics